Leukemia is a type of blood cancer resulting in the abnormal production of blood cells, generally leukocytes (white blood cells). These abnormal cells crowd the bone marrow and other organs such as liver, spleen, and kidneys through blood and prevent its normal functions. There are several types of leukemia that appear suddenly and progress rapidly over days to weeks. Others are less apparent and progress slowly over months to years. Leukemia are named according to the type of blood cells involved. The myeloid leukemia are the ones which involve the granulocytes, red blood cells, platelets, and monocytes and lymphocytic leukemia are those which involve lymphocytes. Leukemia is commonly caused due to the high exposure to radiations, unhealthy lifestyle, genetic factors, and environmental conditions. Leukemia cases are more common in adults and are observed to progress with aging. Thus, increasing geriatric population base and high prevalence of leukemia are the factors driving the leukemia therapeutic market. Moreover, increased innovation and R&D in the oncology sectors and growing number of biotechnology firms are also expected to propel the market growth. Increasing awareness of patients regarding most recent technological developments, introduction of novel therapies and promising pipeline products are the factors expected to further drive the market growth during the forecast period. However, high cost of drugs and treatments along with large number of entry-to-market barriers are some of the challenges faced by the leukemia therapeutic market.